Development of a highly sensitive immuno-PCR assay for the measurement of α-galactosidase a protein levels in serum and plasma

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Nakano, Sachie ^a,b   Morizane, Yoshihito ^a,b   Makisaka, Noriko ^a,b   Suzuki, Toshihiro ^c   Togawa, Tadayasu ^c   Tsukimura, Takahiro ^c   Kawashima, Ikuo ^a   Sakuraba, Hitoshi ^c   Shibasaki, Futoshi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b Synthera Technologies Co Ltd   (Japan)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA-GALACTOSIDASE; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FABRY DISEASE; FEMALE; HUMANS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84893621403     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078588     Document Type: Article

References (34)

1. Desnick RJ, Ioannou YA, Eng CM, editors (2001) α-Galactosidase A deficiency: Fabry disease. Eight ed. New York: McGraw-Hill Inc. 3733-3774 p.
2. Sugawara K, Ohno K, Saito S, Sakuraba H (2008) Structural characterization of mutant alpha-galactosidases causing Fabry disease. J Hum Genet 53: 812-824.
3. Okumiya T, Ishii S, Kase R, Kamei S, Sakuraba H, et al. (1995) Alpha-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins. Hum Genet 95: 557-561.
4. Lee BH, Heo SH, Kim GH, Park JY, Kim WS, et al. (2010) Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. J Hum Genet 55: 512-517.
5. Togawa T, Tsukimura T, Kodama T, Tanaka T, Kawashima I, et al. (2012) Fabry disease: biochemical, pathological and structural studies of the α-galactosidase A with E66Q amino acid substitution. Mol Genet Metab 105: 615-620.
6. Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, et al. (2003) Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat 22: 486-492. (Pubitemid 38009952)
7. Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, et al. (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 97: 365-370. (Pubitemid 30055837)
8. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, et al. (2001) Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345: 9-16. (Pubitemid 32634266)
9. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, et al. (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119: 524-529.
10. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21: 345-354. (Pubitemid 43159987)
11. Fervenza FC, Torra R, Warnock DG (2008) Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics 2: 823-843.
12. Benichou B, Goyal S, Sung C, Norfleet AM, O'Brien F (2009) A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab 96: 4-12.
13. Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, et al. (2008) Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 94: 319-325.
14. Deegan PB (2012) Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis 35: 227-243.
15. Fuller M, Lovejoy M, Brooks DA, Harkin ML, Hopwood JJ, et al. (2004) Immunoquantification of alpha-galactosidase: evaluation for the diagnosis of Fabry disease. Clin Chem 50: 1979-1985. (Pubitemid 39425833)
16. Kitagawa T, Suzuki K, Ishige N, Ohashi T, Kobayashi M, et al. (2008) Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes. Pediatr Nephrol 23: 1461-1471.
17. Ishii S, Kase R, Sakuraba H, Fujita S, Sugimoto M, et al. (1994) Human alpha-galactosidase gene expression: significance of two peptide regions encoded by exons 1-2 and 6. Biochim Biophys Acta 1204: 265-270.
18. Adler M, Wacker R, Niemeyer CM (2003) A real-time immuno-PCR assay for routine ultrasensitive quantification of proteins. Biochem Biophys Res Commun 308: 240-250. (Pubitemid 36937172)
19. Niemeyer CM, Adler M, Wacker R (2005) Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification. Trends Biotechnol 23: 208-216. (Pubitemid 40381284)
20. Sano T, Smith CL, Cantor CR (1992) Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates. Science 258: 120-122.
21. Zhou H, Fisher RJ, Papas TS (1993) Universal immuno-PCR for ultra-sensitive target protein detection. Nucleic Acids Res 21: 6038-6039. (Pubitemid 24023724)
22. Rychlik W, Spencer WJ, Rhoads RE (1990) Optimization of the annealing temperature for DNA amplification in vitro. Nucleic Acids Res 18: 6409-6412.
23. Doi K, Noiri E, Ishizu T, Negishi K, Suzuki Y, et al. (2012) High-throughput screening identified disease-causing mutants and functional variants of alpha-galactosidase A gene in Japanese male hemodialysis patients. J Hum Genet 57: 575-579.
24. Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458.
25. Hendrickson ER, Truby TM, Joerger RD, Majarian WR, Ebersole RC (1995) High sensitivity multianalyte immunoassay using covalent DNA-labeled antibodies and polymerase chain reaction. Nucleic Acids Res 23: 522-529.
26. Sims PW, Vasser M, Wong WL, Williams PM, Meng YG (2000) Immunopolymerase chain reaction using real-time polymerase chain reaction for detection. Anal Biochem 281: 230-232. (Pubitemid 30346503)
27. Ruzicka V, Marz W, Russ A, Gross W (1993) Immuno-PCR with a commercially available avidin system. Science 260: 698-699. (Pubitemid 23167597)
28. Niemeyer CM, Wacker R, Adler M (2003) Combination of DNA-directed immobilization and immuno-PCR: very sensitive antigen detection by means of self-assembled DNA-protein conjugates. Nucleic Acids Res 31: e90.
29. Kim NH, Jung HJ, Shibasaki F, Kwon HJ (2010) NBBA, a synthetic small molecule, inhibits TNF-alpha-induced angiogenesis by suppressing the NF-kappaB signaling pathway. Biochem Biophys Res Commun 391: 1500-1505.
30. Chen L, Endler A, Uchida K, Horiguchi S, Morizane Y, et al. (2010) Int6/eIF3e silencing promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor 2alpha expression. Circulation 122: 910-919.
31. Ohashi T, Sakuma M, Kitagawa T, Suzuki K, Ishige N, et al. (2007) Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol Genet Metab 92: 271-273. (Pubitemid 47513559)
32. Ohashi T, Iizuka S, Ida H, Eto Y (2008) Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol Genet Metab 94: 313-318.
33. Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66: 1589-1595. (Pubitemid 39298394)
34. Rombach SM, Aerts JM, Poorthuis BJ, Groener JE, Donker-Koopman W, et al. (2012) Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso) Gb3 reduction and treatment outcome. PLoS One 7: e47805.